Kuros Biosurgery AG is pleased to announce the close of its first major round of venture capital financing reflecting investor confidence in the Company's technologies and strong patent portfolio. The round was led by Venture Incubator AG, a venture capital fund based in Switzerland that invests in early stage high technology firms in the alpine rim. Further investors included NeoMed from Norway and CDC IXIS Private Equity from France.

Including its corporate collaborations, Kuros has now secured CHF 23.5m (€ 16m) of external financing to advance its technology and product development activities.

Kuros is a private company based in Zurich, Switzerland, developing novel therapies for biosurgery, tissue repair and regeneration. The company is a spin-off from the Swiss Federal Institute, ETHZ and University of Zurich. For more information, please visit www.kuros.ch.